Treatment of Pediatric Hypertension With Altace Trial

NCT00044265

Last updated date
Study Location
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-16 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Males or females age 6 to 16 years. All female subjects ≥ 8 years of age must have a negative urine pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study.

- Weight ≥ 20 kg.

- Parents/guardians must be able to demonstrate their ability to use the home blood pressure device to monitor blood pressure.

- Sitting systolic blood pressure or sitting diastolic blood pressure ≥ the 95th percentile for age, gender and height; or diabetes mellitus or chronic renal insufficiency (as evidenced by GFR 40-70 mL/min/1.73 m2) and a sitting systolic blood pressure or sitting diastolic blood pressure ≥ the 90th percentile for age, gender, and height.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Severe hypertension documented by (1) Sitting systolic blood pressure or sitting
diastolic blood pressure more than 20 mmHg above the 95th percentile for age, gender,
and height without antihypertensive therapy, (2) Sitting systolic blood pressure or
sitting diastolic blood pressure more than 12 mmHg above the 95th percentile for age,
gender, and height while receiving active therapy, or (3) hypertensive encephalopathy
within the previous 5 months.


- Currently receiving more than one antihypertensive medication including: ACE
inhibitors, angiotensin receptor inhibitors, beta blockers, calcium channel blockers,
diuretics.


- Receiving lithium, potassium supplements, monoamine oxidase inhibitors, or major
tranquilizers (Note: Stimulant medications for behavioral disorders, corticosteroids,
and non-steroidal anti-inflammatory agents for chronic pain management are permitted
during the trial provided the subject's dosage is anticipated to remain unchanged
throughout the duration of the study.)


- A history of cardiomyopathy, clinically significant structural heart disease or
atrioventricular conduction disturbance, sick sinus syndrome, atrial flutter, atrial
fibrillation, clinically significant bradycardia or an accessory bypass tract, or
clinical symptoms of congestive heart failure.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

HypertensionAmlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients NCT01200407
  1. San Fernando City, La Union
  2. Taclobo, Dumaguete City, Negros Oriental
  3. Albay,
  4. Angono,
  5. Baguio City,
  6. Baguio,
  7. Bulacan,
  8. Calamba,
  9. Cavite,
  10. Cebu City,
  11. Cebu,
  12. Dagupan,
  13. Davao City,
  14. Davao,
  15. Eastwood,
  16. Iloilo City,
  17. Iloilo,
  18. Isabela,
  19. Kalibo Aklan,
  20. Laguna,
  21. Laoag,
  22. Lingayen, Pangasinan,
  23. Makati City,
  24. Makati City,
  25. Makati,
  26. Mandaluyong,
  27. Manila,
  28. Manila,
  29. Manila,
  30. Manila,
  31. Manila,
  32. Manila,
  33. Marikina City,
  34. Marikina,
  35. Metro Manila,
  36. Muntinlupa,
  37. Nueva Vizcaya,
  38. Olongapo,
  39. Pampanga,
  40. Paranaque,
  41. Parañaque,
  42. Pasay,
  43. Pasig City,
  44. Pasig Ciy,
  45. Pasig,
  46. Pasig,
  47. Puerto Princesa,
  48. Quezon City,
  49. Quezon CIty,
  50. Rizal,
  51. San Juan,
  52. Tacloban,
  53. Taguig,
  54. Tarlac,
  55. Tugegarao,
  56. Tuguegarao City,
  57. Tuguegarao City,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HypertensionA Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents NCT00389519
  1. Little Rock, Arkansas
  2. Little Rock, Arkansas
  3. Beverly Hills, California
  4. Los Angeles, California
  5. Orange, California
  6. Cocoa Beach, Florida
  7. Lakeland, Florida
  8. Atlanta, Georgia
  9. Augusta, Georgia
  10. Honolulu, Hawaii
  11. Park Ridge, Illinois
  12. Tinley Park, Illinois
  13. Louisville, Kentucky
  14. Shreveport, Louisiana
  15. Bridgeton, Missouri
  16. Las Vegas, Nevada
  17. Las Vegas, Nevada
  18. Toms River, New Jersey
  19. Syracuse, New York
  20. Williamsville, New York
  21. Cary, North Carolina
  22. Chapel Hill, North Carolina
  23. Durham, North Carolina
  24. Sylva, North Carolina
  25. Cincinnati, Ohio
  26. Columbus, Ohio
  27. Norman, Oklahoma
  28. Tulsa, Oklahoma
  29. Portland, Oregon
  30. Portland, Oregon
  31. Philadelphia, Pennsylvania
  32. Kingsport, Tennessee
  33. Memphis, Tennessee
  34. Beaumont, Texas
  35. Houston, Texas
  36. Salt Lake City, Utah
  37. Charlottesville, Virginia
  38. Midlothian, Virginia
  39. Norfolk, Virginia
  40. Buenos Aires,
  41. Buenos Aires,
  42. Buenos Aires,
  43. Buenos Aires,
  44. San Juan,
  45. Tucomán,
  46. Santiago,
  47. Santiago,
  48. Santiago,
  49. Vina del Mar,
  50. Barranquilla,
  51. Bogotá,
  52. Bogotá,
  53. Bogotá,
  54. Medellin,
  55. Medellin,
  56. Medellín,
  57. Ahmedabad,
  58. Ahmedabad,
  59. Bangalore,
  60. Chennai,
  61. Delhi,
  62. Delhi,
  63. Delhi,
  64. Hyderabaad,
  65. Hyderabaad,
  66. Ludhiana,
  67. Mumbai,
  68. Pune,
  69. Trivandrum,
  70. Gdansk,
  71. Katowice,
  72. Lodz,
  73. Lodz,
  74. Poznan,
  75. Szczecin,
  76. Szczecin,
  77. Torun,
  78. Warszawa,
  79. Wroclaw,
  80. Benoni,
  81. Johannesburg,
  82. Port Elizabeth,
  83. Potchefstroom,
  84. Pretoria,
  85. Pretoria,
  86. Pretoria,
  87. Pretoria,
  88. Sandton,
  89. Istanbul,
  90. Istanbul,
  91. Izmir,
  92. Samsun,
  93. Dnepropetrovsk,
  94. Kharkov,
  95. Kiev,
  96. Kyiv,
  97. Lviv,
  98. Odessa,
  99. Simferopol,
  100. Uzhorod,
  101. Vinnitsa,
ALL GENDERS
6 Years+
years
MULTIPLE SITES
HypertensionA Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient NCT00415623
  1. Kasuya-gun, Fujuoka
  2. Chikushino, Fukuoka
  3. Kitakyushu, Fukuoka
  4. Koga, Fukuoka
  5. Sapporo, Hokkaidou
  6. Sapporo, Hokkaido
  7. Yokohama, Kanagawa
  8. Iruma, Saitama
  9. Koshigaya, Saitama
  10. Adachi-ku, Tokyo
  11. Edogawa-ku, Tokyo
  12. Meguro-ku, Tokyo
  13. Setagaya-ku, Tokyo
  14. Sumida, Tokyo
  15. Fukuoka,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
HypertensionTreatment of Pediatric Hypertension With Altace Trial NCT00044265
  1. Birmingham, Alabama
  2. Los Angeles, California
  3. Los Angeles, California
  4. Los Angeles, California
  5. Augusta, Georgia
  6. Honolulu, Hawaii
  7. Park Ridge, Illinois
  8. Louisville, Kentucky
  9. New Orleans, Louisiana
  10. Baltimore, Maryland
  11. Detroit, Michigan
  12. Kansas City, Missouri
  13. St. Louis, Missouri
  14. Bronx, New York
  15. Great Neck, New York
  16. Cincinnati, Ohio
  17. Cleveland, Ohio
  18. Cleveland, Ohio
  19. Columbus, Ohio
  20. Portland, Oregon
  21. Hershey, Pennsylvania
  22. Philadelphia, Pennsylvania
  23. Philadelphia, Pennsylvania
  24. Pittsburgh, Pennsylvania
  25. Memphis, Tennessee
  26. Nashville, Tennessee
  27. Houston, Texas
  28. Houston, Texas
  29. Charlottesville, Virginia
  30. Madison, Wisconsin
ALL GENDERS
6 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Treatment of Pediatric Hypertension With Altace Trial
Official Title  ICMJE A Dose Escalation, Randomized, Double-blind Withdrawal Study of the Efficacy, Dose-response, and Safety of Ramipril for the Treatment of Hypertension in Children and Adolescents
Brief Summary Ramipril is an ACE inhibitor that has been marketed in the US for the treatment of hypertension since 1991. It has been shown to be effective in reducing both systolic and diastolic blood pressure in adults when used once daily. ACE inhibitors are frequently used to treat hypertension in children, however ramipril has not been extensively tested in children, and information regarding the efficacy and safety would therefore be of benefit to children. This study is designed to demonstrate the efficacy and safety of ramipril in the treatment of hypertension in children ages 6 through 16 years.
Detailed Description In adults, common side effects include persistent dry mouth, dizziness, fatigue, and headache. Rare cases of angioedema have been reported. When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, ramipril should be discontinued as soon as possible. Ramipril is contraindicated in patients who are hypersensitive to the product or have a history of angioedema related to previous treatment with an ACE inhibitor.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Hypertension
Intervention  ICMJE Drug: ramipril
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: June 23, 2005)
310
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE November 2004
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion criteria:

  • Males or females age 6 to 16 years. All female subjects ? 8 years of age must have a negative urine pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study.
  • Weight ? 20 kg.
  • Parents/guardians must be able to demonstrate their ability to use the home blood pressure device to monitor blood pressure.
  • Sitting systolic blood pressure or sitting diastolic blood pressure ? the 95th percentile for age, gender and height; or diabetes mellitus or chronic renal insufficiency (as evidenced by GFR 40-70 mL/min/1.73 m2) and a sitting systolic blood pressure or sitting diastolic blood pressure ? the 90th percentile for age, gender, and height.

Exclusion criteria:

  • Severe hypertension documented by (1) Sitting systolic blood pressure or sitting diastolic blood pressure more than 20 mmHg above the 95th percentile for age, gender, and height without antihypertensive therapy, (2) Sitting systolic blood pressure or sitting diastolic blood pressure more than 12 mmHg above the 95th percentile for age, gender, and height while receiving active therapy, or (3) hypertensive encephalopathy within the previous 5 months.
  • Currently receiving more than one antihypertensive medication including: ACE inhibitors, angiotensin receptor inhibitors, beta blockers, calcium channel blockers, diuretics.
  • Receiving lithium, potassium supplements, monoamine oxidase inhibitors, or major tranquilizers (Note: Stimulant medications for behavioral disorders, corticosteroids, and non-steroidal anti-inflammatory agents for chronic pain management are permitted during the trial provided the subject's dosage is anticipated to remain unchanged throughout the duration of the study.)
  • A history of cardiomyopathy, clinically significant structural heart disease or atrioventricular conduction disturbance, sick sinus syndrome, atrial flutter, atrial fibrillation, clinically significant bradycardia or an accessory bypass tract, or clinical symptoms of congestive heart failure.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 6 Years to 16 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00044265
Other Study ID Numbers  ICMJE K726-01-4002
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Investigators  ICMJE Not Provided
PRS Account Pfizer
Verification Date June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP